- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07859722
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
A Randomized Pragmatic Study of CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To compare acute changes in patient reported outcomes of urinary toxicity utilizing the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
SECONDARY OBJECTIVES:
I. To compare acute and chronic changes in patient reported outcomes of toxicity utilizing the EPIC-26 Urinary Irritative/Obstructive, Bowel, and Sexual domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
II. To compare the cumulative incidence of physician reported Common Terminology Criteria for Adverse Events (CTCAE) acute and chronic grade 2+ genitourinary (GU) or gastrointestinal (GI) toxicity for patients undergoing prostate HDR brachytherapy planned with utilization of an MRI versus no MRI.
TERTIARY/EXPLORATORY OBJECTIVE:
I. To compare treatment efficacy for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo treatment planning with a CT scan for HDR brachytherapy.
ARM B: Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.
After completion of study intervention, patients are followed up at 1, 3, 6, and 12 months.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Sagar Patel, MD
- Telefoonnummer: 404-778-1900
- E-mail: sagar.patel@emory.edu
Studie Contact Back-up
- Naam: Kamran Salari, MD
- Telefoonnummer: 404-686-2391
- E-mail: kamran.salari@emory.edu
Studie Locaties
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Ardith Deshay
- Telefoonnummer: 404-251-0743
- E-mail: ardith.deshay.deshay@emory.edu
-
Hoofdonderzoeker:
- Kamran Salari, MD
-
Atlanta, Georgia, Verenigde Staten, 30308
- Werving
- Emory University Hospital Midtown
-
Contact:
- Ardith Deshay
- Telefoonnummer: 404-251-0743
- E-mail: ardith.deshay.deshay@emory.edu
-
Hoofdonderzoeker:
- Kamran Salari, MD
-
Atlanta, Georgia, Verenigde Staten, 30308
- Werving
- Emory Proton Therapy Center
-
Contact:
- Ardith DeShay
- Telefoonnummer: 404-251-0743
- E-mail: ardith.deshay.deshay@emory.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Men ≥ 18 years old
- Histopathologically confirmed prostate cancer
- No evidence of regional or distant metastases
- Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy
Exclusion Criteria:
- Prior pelvic radiation therapy
- No prior prostate MRI
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (CT, SOC HDR brachytherapy)
Patients undergo treatment planning with a CT scan for HDR brachytherapy. |
Ancillary studies |
|
Experimenteel: Arm B (CT, MRI, SOC HDR brachytherapy)
Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy. |
Ancillary studies Undergo MRI scan
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Tijdsspanne: At 1 month following treatment
|
The primary analysis will be conducted using a mixed-effects model for repeated measures (MMRM) including fixed effects for treatment arm, categorical time, treatment-by-time interaction, baseline Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence score, age, comorbidity status, and the stratification factors of high-dose-rate treatment approach and rectal spacer use. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. The primary treatment comparison will be the adjusted between-group difference at the 1-month time point derived from the treatment-by-time interaction using least-squares means, with corresponding two-sided 95% confidence intervals and p-values evaluated at a significance level of 0.05. |
At 1 month following treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Tijdsspanne: At 3, 6 and 12 months following treatment
|
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. |
At 3, 6 and 12 months following treatment
|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scores
Tijdsspanne: At 1, 3, 6 and 12 months following treatment
|
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary irritative/obstructive, bowel, and sexual domain scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. |
At 1, 3, 6 and 12 months following treatment
|
|
Cumulative incidence of grade 2 or higher genitourinary or gastrointestinal adverse events
Tijdsspanne: Within 12 months following treatment
|
Will be analyzed using competing-risk methods to account for death as a competing event. Cumulative incidence functions will be estimated for each treatment arm and compared using Gray's test. Fine-Gray subdistribution hazard models, including stratification factors and relevant covariates, will be used to estimate adjusted hazard ratios with 95% confidence intervals. Adverse events will be coded using the Medical Dictionary for Regulatory Activities and graded according to Common Terminology Criteria for Adverse Events version 5.0. Safety analyses will summarize the frequency, severity, and relationship of adverse events to study treatment by System Organ Class and preferred term. Each adverse event will be counted once per participant at the maximum severity grade. Serious adverse events and events leading to treatment discontinuation will be summarized separately. |
Within 12 months following treatment
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Kamran Salari, MD, Emory University Hospital/Winship Cancer Institute
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Prostaatneoplasmata
- Onderzoekstechnieken
- Chemie -technieken, analytisch
- Spectrumanalyse
- Magnetische resonantiespectroscopie
Andere studie-ID-nummers
- 2026P000571
- P30CA138292 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2026-06309 (Register-ID: CTRP (Clinical Trial Reporting Program))
- 2026P000571 (Andere identificatie: Emory University Hospital/Winship Cancer Institute)
- RAD6975-26 (Andere identificatie: Emory University Hospital/Winship Cancer Institute)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .